Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Status:
Unknown status
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of single agent Doxil in the
treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).